Vir Biotechnology launches public stock offering following ECLIPSE 1 Phase 3 resultsNov 12Clinical readoutVir Biotechnology, Inc.Updated
Eikon reports Q3 2026 results, ESMO oncology data and new prostate cancer INDNov 12Quarterly updateAkari Therapeutics PlcAtrium Therapeutics
PepGen reports positive FREEDOM2-DM1 10 mg/kg data, proposes $125M stock offeringNov 10Quarterly updatePepGen IncUpdated
Prime Medicine launches $125 million stock offering, details Wilson disease and AATD progressNov 10FinancingPrime Medicine, Inc.Updated
Adagene completes enrollment in Phase 2 muzastotug dose-optimization trial for MSS colorectal cancerNov 9Trial updateAdagene Inccisplatin
Bicara reaches substantial enrollment in HPV-negative head and neck cancer trialNov 9Quarterly updateArriVent BioPharma, Inc.Bicara Therapeutics
Arvinas reports Q3 2026 results, dosing starts in new HPK1 trialNov 3Quarterly updateARV-6723Arvinas Inc.
Pfizer raises 2026 guidance after Q3, reports pipeline progress and new CFONov 3Quarterly updateBioNTech SEC4 Therapeutics, Inc.
IDEAYA completes darovasertib NDA, halts Phase 3 OptimUM-010 for enrollment issuesNov 3Quarterly updateAlector, Inc.Allogene Therapeutics
Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
UIC registers Phase 1 trial of Pfizer's elranatamab in plasmablastic lymphomaOct 30Weekly roundup, 11 itemsAstellas Pharmaatirmociclib
Imunon agrees to sell ThermoDox rights to VoxelDox TherapeuticsOct 21Clinical readoutEikon TherapeuticsGenmab A/S
Arcus files preliminary prospectus supplement, cites new casdatifan ccRCC dataOct 21Clinical readoutArcus Biosciences, Inc.casdatifanUpdated
Alpha Teknova launches common stock offering, discloses preliminary Q3 2026 resultsOct 21FinancingAlpha Teknova, Inc.
Recursion prices $200M offering, reports Sanofi milestone and TUPELO, DAHLIA dataOct 15Quarterly updateAlector, Inc.REC-1245Updated
AstraZeneca completes Phase 1 laroprovstat/ezetimibe bioavailability study in healthy adultsOct 2Weekly roundup, 6 itemsacalabrutinibanifrolumab-fnia
Novartis: Myfortic label update approved; M.D. Anderson posts endometrial trial resultsJul 31Weekly roundup, 6 itemsabelacimabDDY391
AstraZeneca registers Phase III bladder cancer trial; joins Natera-led breast cancer studyJul 23Weekly roundup, 5 itemsAstraZenecaAZD6489
Gemelli registers interventional EV trial mapping vascular complications in systemic sclerosisJul 21Weekly roundup, 2 itemsMayo Clinic